Detailed price information for Ironwood Pharmaceuti (IRWD-Q) from The Globe and Mail including charting and trades.

(RTTNews) - Ironwood Pharmaceuticals (IRWD), a commercial-stage biotechnology company, today provided guidance for fiscal year 2026, while reaffirming its 2025 outlook, sending the shares to a new ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Shares of Ironwood ...

Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) stock rose Friday with a session volume of 38.35 million compared to the average volume of 2.36 million, as per data from Benzinga Pro. The ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

To better understand which social media platforms Americans use, Pew Research Center surveyed 5,022 U.S. adults from Feb. 5 to June 18, 2025. SSRS conducted this National Public Opinion Reference ...

Your favorite latte at the local coffee shop could soon cost $5, $5.10 or $5.25—depending on how you pay. A settlement between Visa, Mastercard and U.S. merchants announced this week could usher in a ...

– LINZESS® (linaclotide) U.S. net sales of $315 million in Q3 2025, an increase of 40% year-over-year; EUTRx demand growth increased 12% year-over-year – – GAAP net income of $40 million and adjusted ...

The FDA has approved Linzess capsules for treating irritable bowel syndrome with constipation in pediatric patients seven years and older, according to a Nov. 5 news release. Here are five things to ...